On November 6, Novo NordiskRelease 2024 Q3 Financial Report, which disclosed several important pieces of information: 1) The Phase IIIb STRIDE study of semaglutide 1.0mg for the treatment of peripheral artery disease (PAD) has been successfully completed, and a new indication expansion will be applied for in Europe and the US in the first half of 2025; 2) A marketing application for IcoSema (Icodec insulin + semaglutide, once weekly) for the treatment of type 2 diabetes (T2D) has been submitted to the EU; 3) Based on the success of the Phase IIIb FRONTIER 5 study, Novo Nordisk expects to submit the first marketing application for Mim8 to regulatory authorities in 2025.
Specifically, in September, Novo Nordisk successfully completed the 52-week Phase IIIb STRIDE study, which aimed to explore the functional outcome effects of semaglutide versus placebo as an adjunctive therapy to standard treatment in patients with PAD and T2D. Lower extremity PAD, caused by atherosclerosis in the leg arteries, can lead to severe functional impairment, and patients with T2D have a higher risk of developing PAD compared to non-T2D patients.The study met its primary endpoint, showing a statistically significant and clinically relevant 13% improvement in maximum walking distance for patients in the semaglutide group compared to the placebo group. The maximum walking distance increased by 21% in the semaglutide group (baseline: 185 meters) compared to an 8% increase in the placebo group (baseline: 186 meters). Novo Nordisk expects to file for regulatory approval to expand the indication of semaglutide in the U.S. and EU in the first half of 2025.In October, Novo Nordisk submitted a marketing application to the EU for the combination product IcoSema (Icodec insulin + semaglutide, once weekly) for the treatment of T2D.
As early as January this year, Novo Nordisk announced IcoSema vs basal insulin therapy for T2DPhase IIIa COMBINE 3 Study Meets Primary Endpoint. With an overall baseline HbA1c of 8.30%, the estimated HbA1c reduction in the IcoSema group was -1.47%, while the estimated HbA1c reduction in the insulin glargine U100 and insulin aspart group was -1.40% (estimated treatment difference: -0.06%).
In October, Novo Nordisk successfully completed an open-label Phase IIIb FRONTIER 5 study, targeting adult and adolescent patients with hemophilia A with or without inhibitors.This 26-week trial aimed to evaluate the safety of switching from emicizumab prophylaxis to Mim8 prophylaxis. In the trial, the transition from emicizumab to Mim8 was well-tolerated. Additionally, study participants expressed a strong preference for the Mim8 device and noted that the Mim8 pen injector was easy to use. Following interactions with regulatory authorities, Novo Nordisk now anticipates submitting the first approval application for Mim8 in 2025.Results showed that, in hemophilia A patients who had not previously received prophylactic treatment, the number of bleeding episodes was reduced by 97% in the once-weekly Mim8 group and by 99% in the once-monthly Mim8 group compared to the group that did not receive prophylactic treatment.
Copyright © 2024 PHARMCUBE. All Rights Reserved.
Welcome to forward, share, and reasonably cite. When citing, please clearly indicate the source of the article in a prominent position;For reprint, please leave a message or send a message to the WeChat Official Account backend, and indicate the name and ID of the official account.
Disclaimer: The information in this WeChat article is for general reference only and should not be directly used as decision-making content. PharmaCube assumes no responsibility for any loss incurred by any party due to the use of the content herein.
